BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
CNCK
Coincheck Group N.V.
There isn't enough reported data to score CNCK yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CNCK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| N/A | |
| N/A |
CNCK's revenue is currently healthy, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNCK.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
CNCK PE Valuation
CNCK has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over CNCK on the outlook, with more favorable earnings and revenue expectations.
CNCK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Stable | |
| Limited | |
| Low |
Analysts expect CNCK's losses to grow, with revenue declining. However, they disagree widely on these estimates.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over CNCK on earnings quality, reporting a profit while its opponent remains loss making.
CNCK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.06 | +$0.71 |
| Q1 2026 | -$0.09 | +$0.33 |
| Q4 2025 | -$0.00 | -100% |
| Q3 2025 | -$0.76 | -142% |
| Q2 2025 | -$0.77 | -145% |
| Q1 2025 | -$0.42 | -134% |
| Q4 2024 | $0.77 | +1825% |
| Q1 2022 | $16.51 | -60% |
CNCK is still losing money, but far less than before: $0.06 per share over the past year, against $0.77 at its worst in mid-2025.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over CNCK on profitability, with a higher operating margin.
CNCK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $716.6M | +36% |
| Q1 2026 | $750.3M | +4.5% |
| Q4 2025 | $899.2M | +17% |
| Q3 2025 | $834.3M | +89% |
| Q2 2025 | $526.4M | +12% |
| Q1 2025 | $718.2M | +13% |
| Q4 2024 | $771.6M | +108% |
| Q3 2024 | $440.9M | +88% |
CNCK has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1.2% | -0.2 points |
| Q1 2026 | -1.2% | -1.1 points |
| Q4 2025 | 0.6% | +13 points |
| Q3 2025 | 0.7% | +0.7 points |
| Q2 2025 | -1% | -1.9 points |
| Q1 2025 | 0% | -2.4 points |
| Q4 2024 | -12% | -14 points |
| Q3 2024 | 0% | +0.3 points |
CNCK's operating margin was −1.2% last quarter, about level with the same quarter a year ago, near the bottom of its range since 2020.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over CNCK on cash generation, producing positive trailing cash flow while its opponent burns cash.
CNCK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.1M | -277% |
| Q1 2026 | -$2.9M | +$9.1M |
| Q4 2025 | $12.2M | +$16.3M |
| Q3 2025 | -$8.5M | -$3.5M |
| Q2 2025 | $5.2M | +11% |
| Q1 2025 | -$12M | -204% |
| Q4 2024 | -$4.1M | -149% |
| Q3 2024 | -$4.9M | -995% |
CNCK's free cash flow was −$8M over the past year, against −$16M the year before. Free cash flow isn't a meaningful measure for financial services companies like CNCK.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CNCK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CNCK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +41% | +56M shares |
| 1 year | +47% | +61M shares |
| 3 years | +1803% | +182M shares |
| 5 years | +9519% | +190M shares |
CNCK has 192M diluted shares, up 47% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC has the edge over CNCK on leverage, with a lower net debt burden relative to earnings.
CNCK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 85.4x | High |
| Q1 2026 | -66.8x | Net Cash |
| Q3 2024 | 0.0x | Very low |
| Q2 2024 | -2.5x | Net Cash |
| Q1 2024 | 9.9x | High |
| Q4 2023 | -2,695.0x | Net Cash |
| Q4 2022 | 0.0x | Very low |
| Q3 2022 | -5.3x | Net Cash |
CNCK's net debt is more than 20 years of its operating earnings (EBITDA), up from 9.9 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CNCK.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CNCK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.0 | Neutral |
| Stochastic | 2.8 | Oversold |
CNCK's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
CNCK PE vs Financial Services Sector
CNCK has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has stronger trend alignment. BAC is above 1 of 5 weekly averages versus CNCK above 0 of 4.
CNCK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 17% below |
| 20 week MA | $1.85 | 41% below |
| 50 week MA | $2.17 | 49% below |
| 100 week MA | $4.03 | 73% below |
CNCK is in a downtrend: it's below all four of its weekly moving averages, and 73% below its 100-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over CNCK on returns for 2026, with the stronger performance.
CNCK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $13.9 | $8.50 | -39% |
| 2025 | $8.50 | $3.48 | -59% |
| 2026 YTD | $3.48 | $1.10 | -68% |
CNCK has finished every year since 2024 lower, and it's down 68% so far in 2026.